Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Gains from Sales and Divestitures (2024 - 2025)

Insight Molecular Diagnostics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $18000.0 for Q2 2025.

On a quarterly basis, Gains from Sales and Divestitures rose 350.0% to $18000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $18000.0, a 350.0% increase, with the full-year FY2024 number at $17000.0, changed N/A from a year prior.
Gains from Sales and Divestitures hit $18000.0 in Q2 2025 for Insight Molecular Diagnostics, up from $17000.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for IMDX hit a ceiling of $18000.0 in Q2 2025 and a floor of $4000.0 in Q2 2024.